ATEM Capital invests in $80 Million Series B financing of Amolyt Pharma led by Sectoral Asset Management and Andera Partners together with LSP, Orbimed, Pontifax, Kurma Partners, and others to develop therapies that are of vital importance to patients with rare endocrine diseases.
Joseph CAMARDO, M.D.
Dr. Camardo completed medical school at the University of Pennsylvania and is board certified in internal medicine.
He completed his internal medicine internship and residency and his infectious disease fellowship at the University of Colorado.
Ed GODBER, MBA
He holds a master’s degree in health economics from the University of York and a master’s degree in business administration from the London Business School.
Rivka KREITMAN, Ph.D.
Rivka earned her Ph.D. at the Weizmann Institute of Science, Israel (Biochemistry) and postdoctoral work at Princeton University, NJ, US (Molecular Biology).
Prof. Roberto PELLICCIARI
Roberto Pellicciari is a Full Professor of Medicinal Chemistry at the University of Perugia. He was an inventor of Ocaliva®, currently marketed by Intercept Pharmaceuticals to treat Primary Biliary Cirrhosis (PBC). From 2007 to 2008, he has been President of the European Federation of Medicinal Chemistry (EFMC). Before that, Prof. Pellicciari was the President of the Division of Medicinal Chemistry of the Italian Chemical Society.
He received many awards for his research work. In 2005 he was awarded the "Giacomello" prize from the Division of Medicinal Chemistry of the Italian Chemical Society. In 2003 he was awarded the XVI Merz Professorship from the University of Frankfurt. In 1999 he was awarded the "Domenico Marotta" prize of the "Accademia Nazionale delle Scienze detta dei XL". Roberto Pellicciari has published over 300 papers and several international patents.